Avidity Biosciences Inc. (RNA) is scheduled to present new long-term efficacy and safety data from its MARINA-OLE trial at the Muscular Dystrophy Association Clinical & Scientific Conference on March 4, 2024.
MARINA-OLE trial is a Phase 2 extension of the MARINA study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of lead drug candidate AOC 1001 administered intravenously to adult Myotonic Dystrophy Type 1 (DM1) patients.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.